The global Clinical Contract Research Organization (CRO) Services Market is projected to grow from $54 billion in 2024 to $96 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.5%. CROs provide outsourced clinical trial services to pharmaceutical, biotechnology, and medical device companies, managing key aspects such as study design, patient recruitment, clinical monitoring, data management, regulatory compliance, and statistical analysis. The market is segmented by type (Phase I, II, III), application (oncology, infectious diseases, immunological disorders, vaccines, others), and region. Key players include Iqvia, Laboratory Corporation of America Holdings (LabCorp), PPD Inc. (part of Thermo Fisher Scientific), Syneos Health Inc., Wuxi Apptec Co., Ltd., Charles River Laboratories International, Inc., Parexel International Corporation, Pharmaron Beijing Co., Ltd., Icon Plc, Medpace Holdings, Inc., SGS SA, Frontage Holdings Corporation, Psi Cro AG, Bioagile Therapeutics Pvt. Ltd., Firma Clinical Research, Llc, Acculab Life Sciences, Novotech Health Holdings, KCR (formerly Kiecana Clinical Research), Linical Co., Ltd., and Advanced Clinical Direct. North America is the dominant region, while Asia-Pacific is the fastest-growing. The report analyzes market trends, competitive dynamics, and strategic initiatives to support industry expansion.

Eli Lilly faces setbacks after disappointing results for its oral obesity treatment Orforglipron, despite strong financial performance and leadership in the obesity market. The company's injectable treatments outperform Novo Nordisk's, but the oral version's lower efficacy and high dropout rates threaten its competitive position. Eli Lilly remains a top player in the $150bn obesity market, with Zepbound and Mounjaro driving revenue growth.

The page for 'What are IQVIA Holdings Inc. company’s key revenue drivers' could not be found on Jammu Links News. The website displays a 404 error and provides search options for related content.

The article discusses the recent surge in analyst attention towards IQVIA Holdings Inc. stock, though the content appears to be a 404 error page with no valid article text.

The article discusses AI's role in healthcare, emphasizing transparency and ethical data ownership concerns. It features IQVIA's Louise Molloy advocating for clear disclaimers in AI-generated medical information. The piece also highlights recent developments in biopharma, including Eli Lilly's $856M investment, BMS/Pfizer's discounted Eliquis program, Roche's FDA decision on Columvi, Novo Nordisk's sales guidance cut, and regulatory challenges for companies like Replimmune and Rocket.